Risedronic Acid: all 70 studies that test it

Page 1 of 1. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.

• Bisphosphonate Use to Mitigate Bone Loss Secondary to Bariatric SurgeryRecruitingNCT04922333Phase 3
• Effects of Bisphosphonates on OI-Related Hearing LossRecruitingNCT04152551Phase 4
• Prophylactic Risedronate for Patients With Peripheral Lung Tumors Treated With SBRTCompletedNCT03861091Phase 2Results posted
• Weight Loss With Risedronate for Bone HealthCompletedNCT03411902Phase 4Results posted
• Heartland Osteoporosis Prevention StudyCompletedNCT02186600Phase 3Results posted
• A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 TabletsCompletedNCT02063854Phase 2/3Results posted
• Effects of Bisphosphonates and Nutritional Supplementation After a Hip FractureCompletedNCT01950169Not applicableResults posted
• Combination Risedronate - Parathyroid Hormone Trial in Male OsteoporosisCompletedNCT01611571Phase 3Results posted
• IGF-1 and Bone Loss in Women With Anorexia NervosaCompletedNCT01406444Not applicableResults posted
• Effect of Stopping Risedronate After Long Term Treatment on Bone TurnoverCompletedNCT01249261Phase 3Results posted
• Antiepileptic Drugs and Osteoporotic Prevention TrialCompletedNCT00869622Phase 4Results posted
• Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate CancerCompletedNCT00859027Phase 4Results posted
• Efficacy and Safety of Risedronate Therapy Administered 35 mg Once A Week in Men With OsteoporosisCompletedNCT00619957Phase 3Results posted
• Assess the Safety, Efficacy, and Pharmacokinetics of Immediate and Delayed Release Weekly RisedronateCompletedNCT00577720Phase 2Results posted
• Bone Microarchitecture in Osteopenic Postmenopausal WomenTerminatedNCT00577395Phase 4Results posted
• A Study of a 35 mg Delayed Release Formulation of Risedronate for OsteoporosisCompletedNCT00541658Phase 3Results posted
• Effect of Bisphosphonate on Bone Loss in Postmenopausal Women With Breast Cancer Initiating Aromatase Inhibitor TherapyCompletedNCT00485953Phase 4Results posted
• A Study of Actonel for the Prevention of Bone LossCompletedNCT00452439Phase 3Results posted
• Study of the Effect of Once a Week Risedronate on the Microstructure of Tibia and Radius Using a New Scanning MethodCompletedNCT00386360Phase 3Results posted
• Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.CompletedNCT00266708Phase 1/2Results posted
• A Study of Monthly Risedronate for OsteoporosisCompletedNCT00247273Phase 3Results posted
• Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid UseCompletedNCT00221299Phase 4Results posted
• Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal TherapyTerminatedNCT00216060Phase 3Results posted
• Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in ChildrenCompletedNCT00106028Phase 3Results posted
• Bone Loss in Women With Anorexia NervosaCompletedNCT00089843Phase 2/3Results posted
• Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and EfficacyActive, not recruitingNCT07471815Phase 2
• Efficacy and Safety of Actonel® After Denosumab Discontinuation in Postmenopausal Osteoporosis WomenCompletedNCT05630768Phase 4
• Antiresorptive Effect of Treatment With Risedronate and Vitamin D in Postmenopausal PatientsCompletedNCT05346419Not applicable
• Do Bisphosphonates Alter the Skeletal Response to Mechanical Stimulation in Children With Osteogenesis Imperfecta?CompletedNCT03208582Phase 2
• Efficacy of Risedronate in Patients With Painful Periprosthetic Resorption of the Hip ProthesisTerminatedNCT02744482Phase 3
• Short-term Functional Recovery Between Early- and Late Bisphosphonate Treatment Following HemiarthroplastyStatus unknownNCT02148848Phase 4
• Assessment of Response to Treatment of Osteoporosis With Oral Bisphosphonates in Patients With Muscular DystrophyCompletedNCT01882400Phase 4
• Risedronate Therapy in the Treatment of Low Bone Mineral Density in Crohn's DiseaseCompletedNCT01215890Phase 4
• Study to Assess Efficacy of Risedronate in Preventing Bone Loss in Postmenopausal Women Treated for Breast CancerCompletedNCT00859703Phase 3
• A Study to Assess the Bioequivalence of Different Formulations of Risedronate in Healthy Male and Female SubjectsCompletedNCT00846196Phase 1
• Risedronate vs Raloxifene in Hormone Replacement Therapy DiscontinuationTerminatedNCT00790101Phase 4
• Can Risedronate Prevent Periprosthetic Bone Loss After Total Hip ArthroplastyCompletedNCT00772395Phase 4
• Assess the Influence of a High-fat Meal on the Relative Bioavailability Of Two Formulations of RisedronateCompletedNCT00755872Phase 1
• Food Effects on the Relative Bioavailability of Different Dosages of RisedronateCompletedNCT00717145Phase 1
• Assess Bioequivalence of One 150 mg Risedronate Tablet Versus Two 75 mg Risedronate Tablets in Healthy SubjectsCompletedNCT00699777Phase 1
• Bisphosphonate Action on the Appendicular Skeleton: Evidence for Differential EffectsCompletedNCT00666627Phase 2
• A Study to Determine the Satisfaction With Actonel in Postmenopausal Women With OsteoporosisCompletedNCT00632216Phase 4
• Impact of Vertebral Fracture Knowledge on Persistence in Subjects Taking Glucocorticoid TherapyCompletedNCT00616694Phase 4
• Effect of Actonel on Periodontal Health of Postmenopausal WomenWithdrawnNCT00594334Phase 4
• Pharmacokinetics of a Single 14C-labeled Dose of Risedronate or Alendronate Followed by Once-a-week Unlabeled Oral DoseCompletedNCT00577850Phase 1
• Safety, Pharmacokinetics, and Efficacy of 100, 150, and 200 mg Risedronate Administered to Women With Low BMDCompletedNCT00577837Phase 2
• Study to Assess BMD and Bone Turnover Response to 5 mg Daily Risedronate Treatment in Women With PMOCompletedNCT00577421Phase 3
• Prevention of Osteoporosis in Breast Cancer SurvivorsCompletedNCT00567606Not applicable
• Satisfaction and Compliance of Risedronate in PMOCompletedNCT00549965Phase 4
• POWER Point of Care Effect on Satisfaction of TreatmentCompletedNCT00549068Phase 4
• ROSPA - Record on Satisfaction of Patients With Actonel 35 mg Once a WeekTerminatedNCT00544180Phase 4
• SOLID-Effect of Risedronate Sodium at Distal Radius in Colle's Fracture.CompletedNCT00460733Phase 4
• Risedronate Sodium in Post Menopausal OsteoporosisCompletedNCT00453492Phase 4
• Effect of Risedronate on Bone Morbidity in Fibrous Dysplasia of BoneCompletedNCT00445575Phase 2/3
• Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate CancerCompletedNCT00426777Phase 3
• Risedronate in the Prevention of Osteoporosis in Postmenopausal WomenCompletedNCT00402441Phase 4
• The Efficacy of Risedronate in Prevention of Bone Loss in Patients Receiving High Dose Corticosteroid TreatmentCompletedNCT00372372Phase 4
• Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal WomenCompletedNCT00358176Phase 3
• Risedronate In The Prevention Of Osteoporosis In Osteopenic Postmenopausal WomenCompletedNCT00353080Phase 3
• Risedronate in Postmenopausal Women With Low Bone DensityCompletedNCT00351091Phase 2
• Risedronate in Osteopenic Postmenopausal WomenCompletedNCT00345644Phase 3
• Risedronate in Improving Bone Mineral Density and Bone Health in Postmenopausal Women With Ductal Carcinoma In Situ Enrolled in Clinical Trial CRUK-IBIS-II-DCISWithdrawnNCT00324714Phase 3
• IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)CompletedNCT00268632Phase 3
• Isoflavones for Promoting Calcium Absorption and Preventing Bone Loss in Post Menopausal WomenCompletedNCT00244907Phase 1
• Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.CompletedNCT00150696Phase 3
• Risedronate for the Treatment of Osteoporosis for People With Spinal Cord InjuryCompletedNCT00138866Phase 3
• OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal WomenCompletedNCT00130403Phase 4
• Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast CancerCompletedNCT00082277Phase 4
• Risedronate in Preventing Bone Loss in Premenopausal Women Receiving Chemotherapy for Primary Breast CancerCompletedNCT00054418Phase 3
• Calcium With or Without Estrogen and/or Risedronate in Preventing Osteoporosis in Patients With Prostate CancerCompletedNCT00043069Phase 3

← Risedronic Acid overview